Swiss drug major Roche (ROG: SIX) on Wednesday said it has agreed to acquire privately-held Kapa Biosystems for an undisclosed sum in a bid to strengthen its genetic research portfolio.
The company in a statement said Kapa's protein-engineering technology allows for the generation and screening of large numbers of enzyme variants.
Roland Diggelmann, chief operating officer for Roche Diagnostics, said: “Kapa’s technology and products complement our current expertise and offerings such as the portfolio of target enrichment products for next-generation sequencing (NGS).”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze